A Study of LY3041658 in Adults With Hidradenitis Suppurativa

Phase 2 Completed 72 enrolled Eli Lilly and Company

RandomizedParallel-groupDouble-blindTreatment

Summary

The reason for this study is to see if the study drug LY3041658 is effective in participants with moderate-to-severe hidradenitis suppurativa (HS).

Timeline

Start: 2020-08-26
Primary completion: 2022-03-15
Completion: 2022-10-13

Outcome

Missed primary endpoint

registry analysis (superiority test); Placebo vs 600 mg LY3041658; p = 0.189; Mean Difference (Final Values) 17.1 (95% CI -7.3 to 41.4); Regression, Logistic NCT04493502 ↗

paper At week 16, 48.9% of 47 eltrekibart-treated participants and 31.8% of 20 placebo-treated participants achieved HiSCR50 (P = .19). PMID 41061970 ↗

Publications

Forman S, Patel DR, Kimball AB, Jaleel T, Laquer V, Wang T, Zhang Y, Shen L, Nirula A, Klekotka P. A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1/2 ligands, in adults with hidradenitis suppurativa. J Am Acad Dermatol. 2026 Feb;94(2):530-538. doi: 10.1016/j.jaad.2025.10.015. Epub 2025 Oct 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Eltrekibart	Monoclonal antibody	600 mg	Intravenous